Reuters Market Eye - Shares of Divi's Laboratories Ltd
The drugmaker's operating margin fell to 35 percent from 39 percent.
Analysts say management's focus has been more on its Vizag unit, which is awaiting an inspection by the U.S. Food and Drug Administration.
(abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)